Blood Products Advisory Committee.
This article was originally published in The Gray Sheet
Information will be presented March 19 on an emerging infections "plan of action" and FDA will outline its proposal on "plasma inventory hold." The meeting will take place from 8 a.m. to 6 p.m. at the DoubleTree Hotel in Rockville, Maryland. Classification of blood bank software, "relative safety of solvent detergent-treated pooled plasma and single-donor plasma, donor retested," and an FDA proposal on donor deferrals related to xenotransplantation will be discussed on March 20 from 8 a.m. to 3:30 p.m. For more information contact Linda Smallwood at 301/827-3514 or FDA's advisory committee information line at 800/741-8138 and use code 19516...
You may also be interested in...
Policy experts predicted how the incoming Biden administration will handle health care issues at a recent Alliance for Health Policy webinar. Rachel Nuzum, VP of state and federal policy at The Commonwealth Fund, said telehealth could be a priority.
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.